- Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
-
Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi , Hibi T
- KMID: 2417664
- Intest Res.
- 2018 Jul;16(3):499-501.
- doi: 10.5217/ir.2018.16.3.499
The authors regret an error in the reporting of Inflammatory Bowel Disease Questionnaire (IBDQ) patient-reported outcome data in the manuscript. A data extraction error resulted in incorrect IBDQ data being... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis
-
Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S
- KMID: 2539008
- Intest Res.
- 2023 Jan;21(1):88-99.
- doi: 10.5217/ir.2021.00154
Background/Aims: Patients with ulcerative colitis (UC) are at an increased risk of certain infections and malignancies compared with the general population. Incidence rates (IRs) of hospitalized infections, herpes zoster (HZ),... -
- CITED
-
- Close
- SHARE
-
- Close
- Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
-
Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi , Hibi T
- KMID: 2417675
- Intest Res.
- 2018 Apr;16(2):233-245.
- doi: 10.5217/ir.2018.16.2.233
BACKGROUND/AIMS: Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo... -
- CITED
-
- Close
- SHARE
-
- Close
